Citations (28)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (3)
Shannon R. McCurdy & Mark J. Levis. (2018) Emerging molecular predictive and prognostic factors in acute myeloid leukemia. Leukemia & Lymphoma 59:9, pages 2021-2039.
Read now
Read now
Sandhya Annamaneni, Sailaja Kagita, Manjula Gorre, Raghunadha Rao Digumarti, Vishnupriya Satti & Mohan Reddy Battini. (2014) Incidence of internal tandem duplications and D835 mutations of FLT3 gene in chronic myeloid leukemia patients from Southern India. Hematology 19:3, pages 129-135.
Read now
Read now
Aoife Corcoran & Thomas G. Cotter. (2013) FLT3-driven redox-modulation of Ezrin regulates leukaemic cell migration. Free Radical Research 47:1, pages 20-34.
Read now
Read now
Articles from other publishers (25)
D Sorcini, A Stella, A Scialdone, S Sartori, A Marra, R Rossi, F De Falco, FM Adamo, E Dorillo, C Geraci, R Arcaleni, C Rompietti, A Esposito, L Moretti, MG Mameli, MP Martelli, B Falini & P Sportoletti. (2023) FLT3‐targeted therapy restores GATA1 pathway function in NPM1/FLT3‐ITD mutated acute myeloid leukaemia. eJHaem 4:4, pages 1100-1104.
Crossref
Crossref
Konstantin Bogdanov, Ekaterina Kudryavtseva, Yulia Fomicheva, Irina Churkina, Elza Lomaia, Larisa Girshova, Yuri Osipov & Andrey Zaritskey. (2023) Shift of N-MYC Oncogene Expression in AML Patients Carrying the FLT3-ITD Mutation. Pathophysiology 30:3, pages 296-313.
Crossref
Crossref
Ekta Pardhi, Rati Yadav, Akash Chaurasiya, Jitender Madan, Santosh Kumar Guru, Shashi Bala Singh & Neelesh Kumar Mehra. (2023) Multifunctional targetable liposomal drug delivery system in the management of leukemia: Potential, opportunities, and emerging strategies. Life Sciences 325, pages 121771.
Crossref
Crossref
Franziska Schmidt, Miriam Erlacher, Charlotte Niemeyer, Dirk Reinhardt & Jan-Henning Klusmann. (2022) Leukoreductive response to the combination of sorafenib and chemotherapy in hyperleukocytosis of FLT3-ITD mutated pediatric AML. Frontiers in Pediatrics 10.
Crossref
Crossref
Isabella Maria Mayer, Andrea Hoelbl-Kovacic, Veronika Sexl & Eszter Doma. (2022) Isolation, Maintenance and Expansion of Adult Hematopoietic Stem/Progenitor Cells and Leukemic Stem Cells. Cancers 14:7, pages 1723.
Crossref
Crossref
Atia Rehman, Afia Muhammad Akram, Asma Chaudhary, Nadeem Sheikh, Zawar Hussain, Walaa F. Alsanie, Rahat Abdul Rehman, Naila Hameed, Tayyaba Saleem, Amjad Zafar, Muhammad Absar, Zafar Iqbal, Alaa Alhazmi, Hosam Ali Baeshen, Zuhair M Mohammedsaleh, Samina Qamer, Samy Sayed & Ahmed Gaber. (2021) RUNX1 mutation and elevated FLT3 gene expression cooperates to induce inferior prognosis in cytogenetically normal acute myeloid leukemia patients. Saudi Journal of Biological Sciences 28:9, pages 4845-4851.
Crossref
Crossref
David Vetrie, G. Vignir Helgason & Mhairi Copland. (2020) The leukaemia stem cell: similarities, differences and clinical prospects in CML and AML. Nature Reviews Cancer 20:3, pages 158-173.
Crossref
Crossref
Kira Behrens, Katrin Maul, Nilgün Tekin, Neele Kriebitzsch, Daniela Indenbirken, Vladimir Prassolov, Ursula Müller, Hubert Serve, Jörg Cammenga & Carol Stocking. (2017) RUNX1 cooperates with FLT3-ITD to induce leukemia. Journal of Experimental Medicine 214:3, pages 737-752.
Crossref
Crossref
Un‐Beom Kang, William M. Alexander & Jarrod A. Marto. (2017) Interrogating the hidden phosphoproteome. PROTEOMICS 17:6.
Crossref
Crossref
Sam Brondfield, Sushma Umesh, Alexandra Corella, Johannes Zuber, Amy R. Rappaport, Coline Gaillard, Scott W. Lowe, Andrei Goga & Scott C. Kogan. (2015) Direct and indirect targeting of MYC to treat acute myeloid leukemia. Cancer Chemotherapy and Pharmacology 76:1, pages 35-46.
Crossref
Crossref
D Gerloff, R Grundler, A A Wurm, D Bräuer-Hartmann, C Katzerke, J-U Hartmann, V Madan, C Müller-Tidow, J Duyster, D G Tenen, D Niederwieser & G Behre. (2014) NF-κB/STAT5/miR-155 network targets PU.1 in FLT3-ITD-driven acute myeloid leukemia. Leukemia 29:3, pages 535-547.
Crossref
Crossref
Lucas Swanson, Gordon Robertson, Karen L Mungall, Yaron S Butterfield, Readman Chiu, Richard D Corbett, T Roderick Docking, Donna Hogge, Shaun D Jackman, Richard A Moore, Andrew J Mungall, Ka Ming Nip, Jeremy DK Parker, Jenny Qing Qian, Anthony Raymond, Sandy Sung, Angela Tam, Nina Thiessen, Richard Varhol, Sherry Wang, Deniz Yorukoglu, YongJun Zhao, Pamela A Hoodless, S Cenk Sahinalp, Aly Karsan & Inanc Birol. (2013) Barnacle: detecting and characterizing tandem duplications and fusions in transcriptome assemblies. BMC Genomics 14:1.
Crossref
Crossref
Il-Kyoo ParkAnjali MishraJason Chandler, Susan P. Whitman, Guido Marcucci & Michael A. Caligiuri. (2013) Inhibition of the receptor tyrosine kinase Axl impedes activation of the FLT3 internal tandem duplication in human acute myeloid leukemia: implications for Axl as a potential therapeutic target. Blood 121:11, pages 2064-2073.
Crossref
Crossref
Rabab Aly, Dina Shahin & Emad Azmy. (2011) Prognostic significance of FLT3 internal tandem duplication in Egyptian acute myeloid leukemia and normal cytogenetics. Comparative Clinical Pathology 21:5, pages 1029-1035.
Crossref
Crossref
Carolyn A. Felix. 2013. Childhood Leukemias. Childhood Leukemias
723
771
.
Raymond R. Tubbs. 2012. Laboratory Hematology Practice. Laboratory Hematology Practice
155
167
.
Joseph A. Posluszny,Jr.Jr., Richard L. Gamelli & Ravi Shankar. 2012. Total Burn Care. Total Burn Care
277
288.e8
.
Yi Zhang, Manor Askenazi, Jingrui Jiang, C. John Luckey, James D. Griffin & Jarrod A. Marto. (2010) A Robust Error Model for iTRAQ Quantification Reveals Divergent Signaling between Oncogenic FLT3 Mutants in Acute Myeloid Leukemia. Molecular & Cellular Proteomics 9:5, pages 780-790.
Crossref
Crossref
Tara K Gregory, David Wald, Yichu Chen, Johanna M Vermaat, Yin Xiong & William Tse. (2009) Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. Journal of Hematology & Oncology 2:1.
Crossref
Crossref
S. Haihua Chu & Donald Small. (2009) Mechanisms of resistance to FLT3 inhibitors. Drug Resistance Updates 12:1-2, pages 8-16.
Crossref
Crossref
Pamela S. BeckerKenneth J. KopeckyAdrianne N. WilksSylvia ChienJohn M. HarlanCheryl L. WillmanStephen H. Petersdorf, Derek L. Stirewalt, Thalia PapayannopoulouFrederick R. Appelbaum. (2009) Very late antigen-4 function of myeloblasts correlates with improved overall survival for patients with acute myeloid leukemia. Blood 113:4, pages 866-874.
Crossref
Crossref
Aaron Bossler & Vivianna Van Deerlin. 2009. Cell and Tissue Based Molecular Pathology. Cell and Tissue Based Molecular Pathology
33
49
.
David Wald, Johanna M. Vermaat, Gil Peleg & William Tse. (2008) Genetic abnormalities in acute myelogenous leukemia with normal cytogenetics. Current Hematologic Malignancy Reports 3:2, pages 83-88.
Crossref
Crossref
Ulrike Bacher, Claudia Haferlach, Wolfgang Kern, Torsten Haferlach & Susanne Schnittger. (2008) Prognostic relevance of FLT3-TKD mutations in AML: the combination matters—an analysis of 3082 patients. Blood 111:5, pages 2527-2537.
Crossref
Crossref
Dong Wook Kim, Young Suk Jo, Hye Sook Jung, Hyo Kyun Chung, Jung Hun Song, Ki Cheol Park, Su Hyeon Park, Jung Hwan Hwang, So Young Rha, Gi Ryang Kweon, Su-Jae Lee, Ki-Won Jo & Minho Shong. (2006) An Orally Administered Multitarget Tyrosine Kinase Inhibitor, SU11248, Is a Novel Potent Inhibitor of Thyroid Oncogenic RET/Papillary Thyroid Cancer Kinases. The Journal of Clinical Endocrinology & Metabolism 91:10, pages 4070-4076.
Crossref
Crossref